Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of HB-1 for PTSD
NCT07499440Phase 2Recruiting
- Sponsor
- HB Biotech
- Start
- Jun 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HB-01 in post-traumatic stress disorder (PTSD), sponsored by HB Biotech. Started Jun 2026; status: recruiting.
02
Drugs
HB-01
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07499440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499440.